---
title: "Boehringer Ingelheim and Simcere collaborate on dual-target antibody for inflammatory bowel disease, targeting TL1A/IL23p19, to boost efficacy beyond current limits. Strengthened pipeline with new pre-clinic asset."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273832191.md"
description: "Boehringer Ingelheim and Simcere have entered a collaboration to develop a bispecific antibody targeting TL1A and IL23p19 for inflammatory bowel disease. This new pre-clinical asset aims to enhance treatment efficacy beyond current limitations, potentially becoming a first-in-class therapy. The partnership strengthens Boehringer's pipeline in inflammatory diseases, marking a significant advancement in treatment options."
datetime: "2026-01-27T10:41:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273832191.md)
  - [en](https://longbridge.com/en/news/273832191.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273832191.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/273832191.md) | [繁體中文](https://longbridge.com/zh-HK/news/273832191.md)


# Boehringer Ingelheim and Simcere collaborate on dual-target antibody for inflammatory bowel disease, targeting TL1A/IL23p19, to boost efficacy beyond current limits. Strengthened pipeline with new pre-clinic asset.

A recently developed bispecific antibody targeting TL1A and IL23p19 aims to address key drivers of disease pathogenesis in inflammatory bowel disease, potentially surpassing the efficacy limitations seen in current treatments. Boehringer has bolstered its inflammatory disease pipeline through a license and collaboration agreement for this promising pre-clinical asset, marking a significant addition to their portfolio. This novel antibody represents a potential first-in-class treatment, signaling a significant advancement in the field of inflammatory bowel disease treatment.

### Related Stocks

- [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/en/quote/588130.CN.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/en/quote/516500.CN.md)
- [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/en/quote/159992.CN.md)
- [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/en/quote/512290.CN.md)
- [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/en/quote/512010.CN.md)
- [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/en/quote/510660.CN.md)
- [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/en/quote/159859.CN.md)
- [Ping An CSI HK Equities Medical and Health Integration ETF (159718.CN)](https://longbridge.com/en/quote/159718.CN.md)
- [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/en/quote/588250.CN.md)
- [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/en/quote/516930.CN.md)
- [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/en/quote/159892.CN.md)
- [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/en/quote/159102.CN.md)
- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/en/quote/159849.CN.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/en/quote/159837.CN.md)

## Related News & Research

- [SSY Group Wins China Approval for Upadacitinib Bulk Drug](https://longbridge.com/en/news/281103720.md)
- [Annovis Bio Director Purchased Shares Worth Over $1.4M](https://longbridge.com/en/news/281662341.md)
- [Biocytogen and Sihuan partner to advance new therapeutics for weight loss](https://longbridge.com/en/news/281501537.md)
- [Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase](https://longbridge.com/en/news/281231901.md)
- [RemeGen Receives Chinese Regulatory Nod for RC288 Clinical Trial](https://longbridge.com/en/news/281458440.md)